Darnytsia has Registered in Malaysia a Medicine for Comprehensive Treatment of Heart and Kidney Failure

Darnytsia Pharmaceutical Company has registered a medicine that is used in the comprehensive treatment of acute and chronic heart failure, acute and chronic renal failure, nephrotic syndrome, liver diseases, and arterial hypertension, in Malaysia.

Malaysia is a country with multi-level and strict regulation. The first challenges in the registration process arise at the stage of preparing the registration dossier of a medicine, as every report, test and justification must meet strict local requirements and GMP standards.

At the same time, Darnytsia's medicinal products have passed a complicated registration procedure in this country, which once again proves that Ukrainian medicines are non-inferior to globally distributed ones in terms of safety, quality, and efficacy.

We would like to recall that a medicine from Darnytsia for the treatment and prevention of candidiasis infections has been recently registered in Israel. In addition, medicines for the local treatment of acute inflammatory diseases of the oral cavity and throat have successfully passed registration in Moldova. Also, an antibacterial drug for the systemic treatment and prevention of infectious diseases has been registered in Bosnia and Herzegovina.

In general, Darnytsia's high-quality and safe medicines are already trusted in 22 countries around the world.

“We are happy that in 2024 we managed to reveal Darnytsia’s medicines to an increasing number of countries. This is our sixth new country and eighth new registration this year. The year still lasts, and we will make every effort to ensure that as many doctors and patients as possible around the world are convinced of the quality of our medicines,” says Anna Pavliuk-Havrylova, Head of the Department of International Registration and Market Expansion at Darnytsia Pharmaceutical Company.